The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
Open accessAbstract
In a multicenter, randomized, double‐blind trial, the authors compared the antihypertensive efficacy of once‐daily treatment with the new angiotensin II type 1 receptor blocker (ARB) olmesartan (20 mg) with recommended starting doses of losartan (50 mg), valsartan (80 mg), and irbesartan (150 mg) in 588 patients with a cuff diastolic blood pressure (DBP) of ≥100 and ≥115 mm Hg and a mean daytime DBP of ≥90 mm Hg and <120 mm Hg, as measured by ambulatory blood pressure monitoring. Cuff and ambulatory blood pressures were monitored at baseline and after 8 weeks of treatment. All groups were predominantly white and approximately 62% male, and their mean age was approximately 52 years. In all groups, mean baseline DBP and systolic blood pressure (SBP) were approximately 104 and 157 mm Hg, respectively. The reduction of sitting cuff DBP with olmesartan (11.5 mm Hg), the primary efficacy variable of this study, was significantly greater than with losartan, valsartan, and irbesartan (8.2, 7.9, and 9.9 mm Hg, respectively). Reductions of cuff SBP with the four ARBs ranged from 8.4–11.3 mm Hg and were not significantly different. The reduction in mean 24‐hour DBP with olmesartan (8.5 mm Hg) was significantly greater than reductions with losartan and valsartan (6.2 and 5.6 mm Hg, respectively) and showed a trend toward significance when compared to the reduction in DBP with irbesartan (7.4 mm Hg; p=0.087). The reduction in mean 24‐hour SBP with olmesartan (12.5 mm Hg) was significantly greater than the reductions with losartan and valsartan (9.0 and 8.1 mm Hg, respectively) and equivalent to the reduction with irbesartan (11.3 mm Hg). All drugs were well tolerated. The authors conclude that olmesartan, at its starting dose, is more effective than the starting doses of the other ARBs tested in reducing cuff DBP in patients with essential hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
Staessen, J. A., Gasowski, J., Wang, J. G., Thijs, L., Hond, E. D., Boissel, J.-P., Coope, J., Ekbom, T., Gueyffier, F., Liu, L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)07330-4 · Cited by 1,162
Angiotensin II receptor antagonists
Burnier, M., & Brunner, H. (2000) · The Lancet · doi:10.1016/s0140-6736(99)10365-9 · Cited by 707
Prognostic value of 24-hour blood pressure variability
Frattola, A., Parati, G., Cuspidi, C., Albini, F., & Mancia, G. (1993) · Journal of Hypertension · doi:10.1097/00004872-199310000-00019 · Cited by 659
Role of blood pressure in cardiovascular morbidity and mortality
Kannel, W. B. (1974) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(74)90034-6 · Cited by 418
Cited by
Oparil, S., Yarows, S. A., Patel, S., Fang, H., Zhang, J., & Satlin, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61124-6 · Cited by 444
Self-citationDrugs targeting the renin–angiotensin–aldosterone system
Zaman, M. A., Oparil, S., & Calhoun, D. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd873 · Cited by 439
Self-citationKao, D. P., Lewsey, J. D., Anand, I. S., Massie, B. M., Zile, M. R., Carson, P. E., McKelvie, R. S., Komajda, M., McMurray, J. J., & Lindenfeld, J. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.327 · Cited by 274
Bakris, G. L., Sica, D., Weber, M., White, W. B., Roberts, A., Perez, A., Cao, C., & Kupfer, S. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00425.x · Cited by 143
Telemonitoring of blood pressure self measurement in the OLMETEL study
Mengden, T., Ewald, S., Kaufmann, S., vor dem Esche, J., Uen, S., & Vetter, H. (2004) · Blood Pressure Monitoring · doi:10.1097/00126097-200412000-00010 · Cited by 39
Metadata
- Authors
- Oparil, S., Williams, D., Chrysant, S. G., Marbury, T. C., & Neutel, J.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2001-09
- Volume
- 3
- Issue
- 5
- Pages
- 283-318
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- OpenAlex
- W1966000112
- Cited by
- 265
- References
- 25
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. https://app.cochat.ai/papers/10.1111/j.1524-6175.2001.01136.x
- The paper
- Oparil, S., Williams, D., Chrysant, S. G., Marbury, T. C., & Neutel, J. (2001). Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. The Journal of Clinical Hypertension. https://doi.org/10.1111/j.1524-6175.2001.01136.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.